Milestone in Phase I SBIR grant

April 3, 2019

Based on the successful accomplishment of all milestones setup in Phase I SBIR grant, GlycoT was awarded a Phase II SBIR grant (2R44GM123823-01A1, $1,259,261) from the NIH to continue and expand the R&D work to establish a robust and scalable process for production of hypersialylated glycoforms of intravenous immunoglobulin (IVIG) with markedly enhanced anti-inflammatory activity.

Research and Development Collaborations
To request a quote for our products, customized service, investment opportunities, or if you have any general inquiry for our company click the start now button.
Learn More